The trajectory of companies tied to the drug's legacy presents a intricate investment landscape. While the initial surge generated substantial profits , generic alternatives have significantly eroded revenue. Investing in connected pharmaceutical businesses now requires a discerning assessment of intellectual property protection , evolving patient